List/Grid Monthly Archives: August 2010
New frontline high-risk neuroblastoma trial includes MIBG transplant
Pilot study: 131I-MIBG radiotherapy with chemotherapy after induction for newly diagnosed
Dr Greg Yanik (University of Michigan) presented preliminary results of the NANT (New Approaches to Neuroblastoma Therapy) NANT-2001-02 phase 2 MIBG + CEM (131I-MIBG radiotherapy with carboplatin, etoposide, and melphalan) stem cell transplant trial on June 23rd 2010 at the Advances in Neuroblastoma Research ...
ANR 2010 ~ Late Effects of Neuroblastoma Treatment
C10 (p. 80) “Late effects in neuroblastoma”
Dr Lisa Diller (Boston Children’s/Dana-Farber Cancer Institute) reviewed recent published data on late effects and presented new data in the Neuroblastoma Update Course on June 21st, 2010 at the Advances in Neuroblastoma Research meeting in Stockholm, Sweden. The session was organized by Sue Cohn and Andrew Pearson and chaired by Sue Cohn ...
More high-dose 3F8 trials open, one 3F8 trial closed
Memorial-Sloan Kettering (MSKCC) has opened two more high-dose 3F8 trials for neuroblastoma
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
(will accrue 63 patients)
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
(will accrue 53 patients)
MSKCC ...
Two new phase 2 frontline 3F8 trials open at Memorial Sloan-Kettering in NY
High-dose 3F8 trials for high-risk neuroblastoma in first remission
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
The ...
New oncolytic virus clinical trials listed
Three new oncolytic virus trials to treat neuroblastoma: vaccinia (JX-594), herpes simplex (HSV1716), and Newcastle Disease virus
Vaccinia JX-594
A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors
A phase I study using intratumoral injection ...
